Bio-Techne (TE1) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TE1 Analyst Ratings

Hold

0 Buy

11 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Bio-Techne

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TE1 Stock 12 Month Forecast

Average Price Target

€61.73

▼(-2.60% Downside)

Based on 11 Wall Street analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is €61.73 with a high forecast of €62.49 and a low forecast of €55.64. The average price target represents a -2.60% change from the last price of €63.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","48":"€48","53":"€53","58":"€58","63":"€63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62.49234861,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€62.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.73140677000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€61.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.64387205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€55.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,48,53,58,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.649,62.636949893076924,62.62489978615385,62.61284967923077,62.60079957230769,62.588749465384616,62.57669935846154,62.56464925153846,62.552599144615385,62.54054903769231,62.52849893076923,62.516448823846154,62.50439871692308,{"y":62.49234861,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.649,62.57841590538462,62.50783181076923,62.43724771615385,62.366663621538464,62.29607952692308,62.225495432307696,62.15491133769231,62.08432724307693,62.01374314846154,61.94315905384616,61.872574959230775,61.80199086461539,{"y":61.73140677000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.649,62.11014400384615,61.57128800769231,61.03243201153846,60.49357601538462,59.95472001923077,59.41586402307692,58.87700802692308,58.33815203076923,57.79929603461538,57.26044003846154,56.72158404230769,56.18272804615385,{"y":55.64387205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.662,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.693,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.264,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.385,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.264,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.854,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.663,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.09,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.649,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€62.49

Average Price Target€61.73

Lowest Price Target€55.64

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Stampler

Wells Fargo

€53.08→€62.49

Hold

-1.40%

Downside

Downgraded

08/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Minerva Neurosciences (NASDAQ: NERV) and Bio-Techne (NASDAQ: TECH)

Matt Larew

William Blair

―

Hold

―

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Entrada Therapeutics Inc (NASDAQ: TRDA)

Dan Leonard

RBC Capital

€62.49

Hold

-1.40%

Downside

Reiterated

08/12/26

Bio-Techne (TECH) Gets a Hold from RBC Capital

Robert Wasserman

Benchmark Co.

―

Hold

―

Downgraded

06/30/26

Bio-Techne downgraded to Hold from Buy at BenchmarkBio-Techne downgraded to Hold from Buy at Benchmark

Kyle Boucher

TD Cowen

€55.64→€62.49

Hold

-1.40%

Downside

Downgraded

06/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Palvella Therapeutics (NASDAQ: PVLA)

Patrick B Donnelly

Citi

€59.92→€62.49

Hold

-1.40%

Downside

Downgraded

06/29/26

Bio-Techne downgraded to Neutral from Buy at CitiBio-Techne downgraded to Neutral from Buy at Citi

Catherine Ramsey Schulte

Robert W. Baird

€41.95→€62.49

Hold

-1.40%

Downside

Reiterated

06/26/26

Bio-Techne price target raised to $73 from $49 at BairdBio-Techne price target raised to $73 from $49 at Baird

Steven Etoch

Stephens

€58.21→€62.49

Hold

-1.40%

Downside

Downgraded

06/26/26

Bio-Techne downgraded to Equal Weight from Overweight at StephensBio-Techne downgraded to Equal Weight from Overweight at Stephens

Justin Bowers

Deutsche Bank

€56.5→€62.49

Hold

-1.40%

Downside

Downgraded

06/26/26

Bio-Techne downgraded to Hold from Buy at Deutsche BankBio-Techne downgraded to Hold from Buy at Deutsche Bank

Puneet Souda

Leerink Partners

€62.49

Hold

-1.40%

Downside

Downgraded

06/25/26

Bio-Techne downgraded to Market Perform from Outperform at LeerinkBio-Techne downgraded to Market Perform from Outperform at Leerink

David Westenberg

Piper Sandler

€55.64

Hold

-12.21%

Downside

Initiated

06/11/26

Bio-Techne initiated with a Neutral at Piper SandlerBio-Techne initiated with a Neutral at Piper Sandler

Daniel Arias

Stifel Nicolaus

€55.64→€42.8

Hold

-32.47%

Downside

Reiterated

05/07/26

Bio-Techne price target lowered to $50 from $65 at StifelBio-Techne price target lowered to $50 from $65 at Stifel

Daniel Markowitz CFA

Evercore ISI

€46.23→€42.8

Hold

-32.47%

Downside

Assigned

05/07/26

Bio-Techne price target lowered to $50 from $54 at Evercore ISIBio-Techne price target lowered to $50 from $54 at Evercore ISI

Paul Knight

KeyBanc

―

Hold

―

Reiterated

05/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and Bio-Techne (NASDAQ: TECH)

David Toung

Argus Research

€55.64→€58.21

Buy

-8.15%

Downside

Assigned

11/20/25

Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Stampler

Wells Fargo

€53.08→€62.49

Hold

-1.40%

Downside

Downgraded

08/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Minerva Neurosciences (NASDAQ: NERV) and Bio-Techne (NASDAQ: TECH)

Matt Larew

William Blair

―

Hold

―

Reiterated

08/12/26

Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Entrada Therapeutics Inc (NASDAQ: TRDA)

Dan Leonard

RBC Capital

€62.49

Hold

-1.40%

Downside

Reiterated

08/12/26

Bio-Techne (TECH) Gets a Hold from RBC Capital

Robert Wasserman

Benchmark Co.

―

Hold

―

Downgraded

06/30/26

Bio-Techne downgraded to Hold from Buy at BenchmarkBio-Techne downgraded to Hold from Buy at Benchmark

Kyle Boucher

TD Cowen

€55.64→€62.49

Hold

-1.40%

Downside

Downgraded

06/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Palvella Therapeutics (NASDAQ: PVLA)

Patrick B Donnelly

Citi

€59.92→€62.49

Hold

-1.40%

Downside

Downgraded

06/29/26

Bio-Techne downgraded to Neutral from Buy at CitiBio-Techne downgraded to Neutral from Buy at Citi

Catherine Ramsey Schulte

Robert W. Baird

€41.95→€62.49

Hold

-1.40%

Downside

Reiterated

06/26/26

Bio-Techne price target raised to $73 from $49 at BairdBio-Techne price target raised to $73 from $49 at Baird

Steven Etoch

Stephens

€58.21→€62.49

Hold

-1.40%

Downside

Downgraded

06/26/26

Bio-Techne downgraded to Equal Weight from Overweight at StephensBio-Techne downgraded to Equal Weight from Overweight at Stephens

Justin Bowers

Deutsche Bank

€56.5→€62.49

Hold

-1.40%

Downside

Downgraded

06/26/26

Bio-Techne downgraded to Hold from Buy at Deutsche BankBio-Techne downgraded to Hold from Buy at Deutsche Bank

Puneet Souda

Leerink Partners

€62.49

Hold

-1.40%

Downside

Downgraded

06/25/26

Bio-Techne downgraded to Market Perform from Outperform at LeerinkBio-Techne downgraded to Market Perform from Outperform at Leerink

David Westenberg

Piper Sandler

€55.64

Hold

-12.21%

Downside

Initiated

06/11/26

Bio-Techne initiated with a Neutral at Piper SandlerBio-Techne initiated with a Neutral at Piper Sandler

Daniel Arias

Stifel Nicolaus

€55.64→€42.8

Hold

-32.47%

Downside

Reiterated

05/07/26

Bio-Techne price target lowered to $50 from $65 at StifelBio-Techne price target lowered to $50 from $65 at Stifel

Daniel Markowitz CFA

Evercore ISI

€46.23→€42.8

Hold

-32.47%

Downside

Assigned

05/07/26

Bio-Techne price target lowered to $50 from $54 at Evercore ISIBio-Techne price target lowered to $50 from $54 at Evercore ISI

Paul Knight

KeyBanc

―

Hold

―

Reiterated

05/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and Bio-Techne (NASDAQ: TECH)

David Toung

Argus Research

€55.64→€58.21

Buy

-8.15%

Downside

Assigned

11/20/25

Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Techne

3 Months

OpenAI BiotechnologyTipRanks - OpenAI

Success Rate

3/4 ratings generated profit

Average Return

-1.00%

Copying OpenAI Biotechnology's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of -1.00% per trade.

1 Year

OpenAI BiotechnologyTipRanks - OpenAI

Success Rate

3/4 ratings generated profit

Average Return

-1.00%

Copying OpenAI Biotechnology's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of -1.00% per trade.

2 Years

OpenAI BiotechnologyTipRanks - OpenAI

Success Rate

3/4 ratings generated profit

Average Return

-1.00%

Copying OpenAI Biotechnology's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of -1.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TE1 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TE1 has received 3 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. TE1 average Analyst price target in the past 3 months is 61.73.

Each month's total comprises the sum of three months' worth of ratings.

TE1 Financial Forecast

TE1 Earnings Forecast

Next quarter’s earnings estimate for TE1 is €0.38 with a range of €0.36 to €0.40. The previous quarter’s EPS was €0.45. TE1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TE1 has Performed in-line its overall industry.

TE1 Sales Forecast

Next quarter’s sales forecast for TE1 is €250.41M with a range of €246.15M to €252.58M. The previous quarter’s sales results were €275.38M. TE1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TE1 has Performed in-line its overall industry.

TE1 Stock Forecast FAQ

What is DE:TE1’s average 12-month price target, according to analysts?

Based on analyst ratings, Bio-Techne’s 12-month average price target is 61.73.

What is DE:TE1’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:TE1, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bio-Techne a Buy, Sell or Hold?

Bio-Techne has a consensus rating of Hold, which is based on 0 buy ratings, 11 hold ratings and 0 sell ratings.

What is Bio-Techne’s share price target?

The average share price target for Bio-Techne is 61.73. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €62.49 ,and the lowest forecast is €55.64. The average share price target represents -2.60% Decrease from the current price of €63.38.

What do analysts say about Bio-Techne?

Bio-Techne’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Bio-Techne?

To buy shares of DE:TE1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bio-Techne (TE1) Stock Forecast & Price Target

TE1 Analyst Ratings

TE1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bio-Techne

TE1 Analyst Recommendation Trends

TE1 Financial Forecast

TE1 Earnings Forecast

TE1 Sales Forecast

TE1 Stock Forecast FAQ

Detailed List of Analyst Forecasts